The Association of Industry Payments to Physicians with Prescription of Brand‐Name Intranasal Corticosteroids. (5th June 2018)

• Record Type: Journal Article
• Authors: Morse, Elliot; Fujiwara, Rance J. T.; Mehra, Saral
• Is Part Of: Otolaryngology--head and neck surgery. Volume 159:Number 3(2018)
• Page Start: 442
• Page End: 448
• Publication Date: 2018-06-05
• Subjects: industry -- Open Payments Database -- Sunshine Act -- allergic rhinitis -- nasal steroids -- conflict of interest; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599818774739
• Languages: English
• ISSNs: 0194-5998

Abstract

Abstract : Objectives: To examine the association of industry payments for brand‐name intranasal corticosteroids with prescribing patterns. Study Design: Cross‐sectional retrospective analysis. Setting: Nationwide. Subjects and Methods: We identified physicians prescribing intranasal corticosteroids to Medicare beneficiaries 2014‐2015 and physicians receiving payment for the brand‐name intranasal corticosteroids Dymista and Nasonex. Prescription and payment data were linked by physician, and we compared the proportion of prescriptions written for brand‐name intranasal corticosteroids in industry‐compensated vs non‐industry‐compensated physicians. We associated the number and dollar amount of industry payments with the relative frequency of brand‐name prescriptions. Results: In total, 164, 587 physicians prescribing intranasal corticosteroids were identified, including 7937 (5%) otolaryngologists; 10, 800 and 3886 physicians received industry compensation for Dymista and Nasonex, respectively. Physicians receiving industry payment for Dymista prescribed more Dymista as a proportion of total intranasal corticosteroid prescriptions than noncompensated physicians (3.1% [SD = 9.6%] vs 0.2% [SD = 2.5%], respectively, P <. 001). Similar trends were seen for Nasonex (12.0% [SD = 16.8%] vs 4.8% [SD = 13.6%], P <. 001). The number and dollar amount of payment were significantly correlated to the relative frequency of Dymista (ρ = 0.26, P <. 001 and ρ = 0.20, P <. 001, respectively) and Nasonex prescriptions (ρ = 0.09, P <. 001 and ρ = 0.15, P <. 001, respectively). For Dymista, this association was stronger in otolaryngologists than general practitioners ( P <. 001). There was a stronger correlation between the percentage of prescriptions and the number and dollar amount of payments for Dymista than for Nasonex ( P =. 014 and P <. 001). Conclusions: Industry compensation for brand‐name intranasal corticosteroids is significantly associated with prescribing patterns. The magnitude of association may depend on physician specialty and the drug's time on the market.